|
Statement
| 1.Date of occurrence of the event:2022/04/13
2.Company name:TTY Biopharm Co., Ltd.
3.Relationship to the Company (please enter "head office" or
"subsidiaries"):Head office
4.Reciprocal shareholding ratios:N/A
5.Cause of occurrence:TTY Biopharm posted a consolidated net sales of
$367,243 thousands(expressed in NT dollars; unaudited), a consolidated
operating profit of $81,126 thousands, and a consolidated income
before tax of $109,405 thousands in Mar 2022; net income attributed to
stockholders of the company was $88,323 thousands; EPS is $0.36.
Year-to-date consolidated net sales was $1,037,117 thousands (in NT
dollars; unaudited), a consolidated operating profit was $246,564
thousands and consolidated income before tax was $287,248 thousands
until Mar 2022; year-to-date net income attributed to stockholders
of the company was $227,508 thousands; EPS is $0.91.
6.Countermeasures:None.
7.Any other matters that need to be specified:The numbers above are unaudited.
In term of the final net sales and profits, quarterly financial reports
audited by independent accountants will prevail.
|
